Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 65 or older who are able to reliably attend appointments and follow the trial requirements
- People who have had breast-conserving surgery (surgery that removes the tumour but keeps most of the breast)
- People whose cancer is at an early stage (classified as T1 or T2) and has not spread to the lymph nodes
- People with a specific tumour type known as "Luminal A" (a slower-growing, hormone-sensitive breast cancer type — confirm with trial site)
- People whose surgery successfully removed all cancer with clear edges around the tumour (negative margins)
- People for whom the recommended treatment is radiation to the whole breast only
- People whose cancer has been confirmed to have not spread to other parts of the body
- People who live close enough to the trial site to attend follow-up appointments
- People who have signed and dated a consent form agreeing to take part
- People who are registered with the French social security system
Who may not be able to join:
- People whose cancer has spread to distant parts of the body (metastases)
- People who require radiation treatment to the lymph nodes
- People who have cancer in both breasts at the same time
- People who have had a full breast removal (mastectomy)
- People who received chemotherapy or other cancer treatment before their surgery (neoadjuvant therapy)
- People who have had another type of cancer (other than breast cancer) within the past 3 years — except for certain treated skin cancers or early-stage cervical changes, and only if they have been cancer-free for at least three years
- People with serious ongoing or untreated health conditions — such as heart, kidney, liver, or lung problems — that would make long-term follow-up unsafe or difficult
- People who have taken part in another drug trial within the past 30 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Céline BOURGIER, MD, Institut Régional du Cancer de Montpellier (ICM)
Phone: 0467613102
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Acute and late breast fibrosis rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.